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Abstract  
BACKGROUND: With a frequency of 1:1600, the alpha-1-antitrypsin deficiency is one of the 
most frequent hereditary diseases and can be recessively inherited. AAT deficiency is most 
often caused by inheritance of the so-called PiZ allele. Inheritance of this allele increases the 
risk of developing chronic obstructive pulmonary diseases (COPD) and liver disease. 
AIM: The aim of this study was to present immunonephelometry and reverse hybridization 
genotyping in diagnosis of alpha-1-antitrypsin deficiency in Republic of Macedonia. 
MATERIAL AND METHODS: At the Institute of Immunobiology and Human Genetics, part of 
the Faculty of Medicine in Skopje, in the previous 7 years, total of 361 patients with suspected 
alpha-1-antitrypsin (AAT) deficiency were referred for analysis of AAT concentration using 
nephelometry (Dade Behring) and subsequent AAT genotyping of individuals with alpha-1-
antytripsin deficiency at protein level, based on reverse hybridization technique. 
RESULTS: Measurement of AAT concentration (g/l) by nephelometry have shown normal level 
in the range of 1.37-1.41 g/l (88%), lower than normal AAT levels in the range of 0.70-0.83 g/l 
(8.03%), and concentration above the normal levels in the range of 2.28-2.4 g/l (3.88%). 
CONCLUSION: Diagnosis in the case of a suspicion of AAT deficiency is carried out by 
measuring the alpha-1-antitrypsin level in blood and by genotyping of alpha-1-antytripsin allele. 
 
 
 
 
 
 
Introduction 
  
Alpha-1-antitrypsin (AAT) is a member of the 
serine protease inhibitor family (Pi), deficiency of 
which is associated with chronic pulmonary disease 
(emphysema) and liver disease [1, 2]. AAT is 
produced in the liver, released into the circulation and 
enters the lungs by diffusion, where it inhibits 
neutrophil elastase [3]. AAT is a 394 amino acid, 52 
kDa acute phase glycoprotein encoded on the long 
distal arm of the chromosome 14 (14q32.1) [4]. 
With a frequency of 1:1600, the alpha-1-
antitrypsin deficiency is one of the most frequent 
hereditary diseases and can be recessively inherited. 
AAT deficiency is most often caused by inheritance of 
the so-called PiZ allele. Inheritance of this allele 
increases the risk of developing chronic obstructive 
pulmonary diseases (COPD) and liver disease. Little 
is known about the pathogenesis, as not all people 
affected actually fall ill. The examination of twins 
shows that exogenic factors affect the course of 
disease [5, 6]. 
The most cases of alpha-1-antitrypsin 
deficiency are caused by homozygosis for the 
deficient allele PiZ or by heterozygosis combination of 
the 2 most common deficient alleles, PiS and PiZ. In 
the present of Z allele, however, further decreases 
AAT concentrations occur and may lead to 
uncontrolled elastase activity and proteolytic  damage 
in the lower respiratory tract [7, 8], increasing the risk 
for developing COPD. The S allele is a deficiency 
allele attributable to intracellular degradation [9, 10]. 
Patients homozygous for the S allele have AAT 
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concentration ~10%-20% below those typically 
observed in individuals homozygous for nondeficiency 
allele. Around 25% of all children with a complete 
alpha-1-antitrypsin deficiency (homozygous PiZ 
mutation) develop liver cirrhosis, and approximately 
75% of the affected adults suffer from chronic 
obstructive pulmonary diseases [11, 12]. 
PiZ is by far the most common and significant 
deficiency allele with great clinical importance. The 
PiS allele, also frequent, seems only to be relevant in 
combination with PiZ, as exclusively PiS homozygos 
patients are not usually affected. Heterozygous PiMZ 
and PiSZ carriers are usually clinically inconspicuous 
or suffer only slightly, unless they smoke. 
Heterozygous carriers who smoke develop in the 
majority of cases chronically obstructive pulmonary 
diseases, comparable to those of clinically 
homozygous non-smoking carriers. Personal smoking 
has the most dramatic effect on health status of PiZ/Z 
individuals. PiZ/Z individuals who smoke cigarettes 
die 20 years earlier than PiZ/Z nonsmokers [13]. 
Environmental risk factors for progression of lung 
disease among individuals with a Z allele include 
personal smoking, passive smoke exposure especially 
as a child and mineral dust exposure [14-17].  
 
Figure 1: Serum concentration of AAT according PI genotype. On 
the X axis, the main PI genotypes are given, and on the Y axis the 
corresponding plasma concentration of AAT are shown as a 
proportion of the normal range. The risk of pulmonary disease 
increases with the ratio dropping below 35%. 
 
A common AAT classification divides the Pi 
variants into 4 categories:  
           1. Normal variants, characterized by normal 
plasma concentrations of AAT, for which there is no 
increased risk of developing lung or liver disease. This 
category includes the M genotypic variant and sub 
variants. 
            2. Deficient variants, characterized by lower 
then normal but detectable       concentrations of AAT. 
This group mainly includes the PiS and PiZ variants. 
The PiZ variant associated with increased risk of lung 
or liver disease because it expresses approximately 
10% to 20% AAT. The PiS variant, which is more 
common in the Mediterranean region, expresses 
approximately 50% to 60% AAT. 
            3.  Null variants, associated with undetectable 
concentrations of AAT in plasma and with highest risk 
of emphysema. 
            4. Dysfunctional variants, characterized with 
normal amount of AAT, which                                         
does not function properly.  
The protein level in serum and the enzyme 
activity depend on the genotype and are distributed in 
a broad range from 0 to 100% [18] (Figure 1). 
The aim of this study was to present 
immunonephelometry and reverse hybrydization 
genotyping in diagnosis of alpha-1-antitrypsin 
deficiency in Republic of Macedonia. 
 
 
Material and Methods 
 
At Institute of Immunobiology and Human 
Genetics, part of the Faculty of Medicine in Skopje, in 
the previous 7 years, total of 361 patients with 
suspected alpha-1-antitrypsin (AAT) deficiency were 
referred for analysis of AAT concentration using 
neohelometry (Dade Behring) and subsequent AAT 
genotyping of individuals with alpha-1-antytripsin 
deficiency at protein level, based on reverse 
hybridization technique. Samples of whole blood (for 
AAT genotyping) and serum (for measurement of AAT 
concentration) were collected for each patient. 
Six millilitres of blood were drawn from the 
patient and his first degree-relatives, by venepunction, 
after signing a written consent. Genomic DNA was 
isolated from the peripheral blood leukocytes using 
phenol-chlorophorm extraction method [19]. The 
samples of DNA were subsequently stored in the 
Macedonian Human DNA Bank [20]. The detection of 
the alpha-1-antytripsin deficiency alleles PiS and PiZ 
was performed using the commercial Alpha-1-
antytripsin kit RDB2010E (GenID GmbH, Straβberg, 
Germany), based on reverse hybridization technique 
[21, 22]. 
Using the kit, alpha-1-antytripsin deficiency 
alleles PiS and PiZ were detected, by means of a total 
of 8 DNA probes. The test shows the presence or 
absence of mutations which encode the exchange of 
amino acids from glutamic acid to lysine at codon 342 
(PiZ), and from glutamic acid to valine at codon 264 
(PiS). The GenID alpha-1-antytripsin test enables a 
reliable detection and differentiation of both 
homozygous and heterozygous characteristics. It is 
based on the polymerase chain reaction (PSR) 
method with hybridization subsequently [21]. 
A PCR is first carried out using isolated DNA. 
In this multiplex reaction two fragments of the Alpha-
1-antytripsin gene are amplified with specific, biotin-
labeled primers. The characterization of the amplified 
gene fragments takes place in a hybridizing reaction 
with sequence-specific oligonucleotide probes 
(SSOP), which were immobilized on nitrocellulose 
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strip (reverse hybridization). Immobilized probes are 
specific for the PiM allele (wild type), PiZ (mutation), 
the wild type and mutated sequence of the S-locus, as 
well as various control zones. 
During hybridization, the denatured amplified 
DNA binds to the gene probes attached to the strips. 
A highly specific washing procedure ensures that the 
hybrids only survive if the probe’s sequence is 100% 
complementary to that of the amplified DNA. 
Streptavidin-coupled alkaline phosphatase binds to 
the hybrids of gene probe and  biotin-labeled amplified 
DNA. This complex then was detected by a colour 
reaction of BCIP/NBT at the alkaline phosphatase. 
The band pattern was analyzed using the template 
supplied. A total of eight reaction zones were defined 
and capable of development (Figure 2).  
 
Figure 2: Control zones and gene probes on the nitrocellulose strip. 
 
Conjugate control, Sensitivity control PiM/Z 
and Sensitivity control PiS are reactions zones who 
must always be developed. The first of them 
documents the efficiency of the conjugate bonding. 
The second and third reactions zones document the 
optimal sensitivity of the hybridization and function as 
an amplification control. Specificity control is reaction 
zone which is only developed if the washing 
temperature is too low. It indicates an unspecific 
hybridization. PiM (wild type) and PiZ (mutation) are 
reaction zones which are developed if the wild type 
sequence PiM apropos mutated sequence PiZ is 
present. If the patient has heterozygous 
characteristics, the reaction zone ,,PiM” is also 
developed. PiS negative (wild type) and PiS positive 
(mutation) are reaction zones which are developed if 
the wild type PiS sequence apropos mutated PiS 
sequence is present. If the patient has heterozygous 
characteristics, the reaction zone ,,PiS negative” is 
also developed. A strongly reduced or non-existent 
concentration of the protein points to a homozygous 
defect. The AAT concentration in heterozygous 
patients is usually in the lower normal region. Since 
the measurement of the alpha-1-antytripsin level in 
blood is not appropriate for identifying heterozygous 
carriers, certain diagnosis can only be achieved by 
typing the alpha-1-antytripsin allele [22]. 
For measurement on alpha-1-antytripsin level 
in blood we used nephelometry on a Behring 
Nephelometer (BN ProSpec) with a commercially 
available standard and monospecific antisera (Dade 
Behring), according to the manufacturer
’
 s 
instructions.  Nephelometry is the most commonly 
used measurement principle for the immunochemical 
determination of protein in serum, urine and other 
body fluids. It is also the most accurate one. In this 
method, the light which is scattered by the antigen-
antibody complexes is measured. If a sample 
containing antigen and the corresponding antiserum 
are put into a cuvette, antigen-antibody complexes are 
formed. A light beam is generated by means of a laser 
diode, and this is then sent through the cuvette. The 
light is scattered by the antigen-antibody complexes 
which are present. The intensity distribution of the 
scattered light depends on the relationship of the 
particle size of the antigen-antibody complexes to the 
wavelength. Heidelberger-Kendall curve shows the 
relationship between the antigen level and the 
measurement signal at a constant antibody level. In 
the evaluation on the Heidelberger-Kendall curve, two 
antigen concentrations could therefore be responsible 
for a particular measurement signal: 
 The first point lies on the ascending branch in 
the antibody excess range (low antigen 
concentration). 
 The second point lies on the descending 
branch in the antigen excess range (high 
antigen concentration) (Figure 3). 
  
 
Figure 3: Heidelberger-Kendall curve. 
 
 
Results 
 
Measurement of AAT concentration (g/l) by 
nephelometry have shown normal level in the range of 
1.37-1.41 g/l (88%),  lower  than  normal AAT levels in  
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Figure 4: Frequency distribution of AAT serum concentration of 361 samples, analyzed by immunonephelometry. 
 
the range of 0.70-0.83 g/l (8.03%), and concentration 
above the normal levels was seen in the range of 
2.28-2.4 g/l (3.88%). Measurement of AAT 
concentration (g/l) by nephelometry have shown 
normal level in the range of 1.37-1.41 g/l (88%), lower 
than normal AAT levels in the range of 0.70-0.83 g/l 
(8.03%), and concentration above the normal levels 
was seen in the range of 2.28-2.4 g/l (3.88%) (Figure 
4). The genotype assay was interpreted with respect 
to the PiM, PiZ and PiS alleles. Results of measured 
AAT concentration by nephelometry and AAT 
genotyping with reverse hybridization technique are 
showed in the Table 1. 
Table 1: Results of samples with measured AAT concentration 
(g/l) and their AAT genotyping. 
Sample ID AAT concentration, g/l Genotype Results 
AT001 0.50 PiZ/Z//PiSN 
AAT004 0.70 PiM/Z 
AAT005 0.89 PiM/Z; PiSN/P 
AAT006 1.13 PiM/M; PiSN 
AAT007 0.88 PiM/M; PiSN 
AAT008 1.19 PiM/Z; PiSN/P 
AAT009 1.50 PiM/Z; PiSN/P 
AAT010 0.61 PiM/Z; PiSN/P 
AAT011 0.70 PiM/Z; PiSN/P 
AAT014 1.19 PiM/Z; PiSN/P 
AAT017 0.51 PiM/Z; PiSN/P 
 
An individual with a PiZ/Z genotype is 
homozygous for the PiZ variation and homozygous for 
the wild-type allele at the codon associated with the 
PiS alleles (PiS/N-,,PiS negative”). A similar 
interpretation is made for an individual with an PiS 
genotype (PiS/P-,,PiS positive”). If neither the PiZ nor 
PiS/P allele is detected, it is likely that the individual 
possesses 2 wild-type alleles PiM/M and PiS/N. If one 
PiZ and PiM allele is detected, the individual is 
interpreted as having a PiM/Z genotype, otherwise 
referred to as a PiZ heterozygote. This individual is 
heterozygous for the PiZ variation and homozygous 
for the wild-type allele at the codon associated with 
the PiS alleles (PiS/N-,,PiS negative”). A similar 
interpretation is made for an individual in whom two 
PiS alleles is detected (PiS/N/P). 
 
Discussion 
 In this paper we presented our results from 
immunonephelometry and reverse hybrydization 
genotyping in diagnosis of alpha-1-antitrypsin 
deficiency in Republic of Macedonia. Measurement of 
AAT concentration (g/l) by nephelometry have shown 
normal level in 88%, lower than normal AAT levels in 
8.03%, and concentration above the normal levels 
was seen in 3.88%. We described for the first time in 
Republic of Macedonia parallel investigation of AAT 
concentration in serum and genotypes of SERPINA1 
gene. 
 The SERPINA1 gene (*107400) encodes 
alpha-1-antitrypsin (AAT), also known as protease 
inhibitor (PI), a major plasma serine protease inhibitor. 
AAT complexes predominantly with elastase, but also 
with trypsin, chymotrypsin, thrombin, and bacterial 
proteases. The most important inhibitory action of 
AAT is that against neutrophil elastase (ELANE, or 
HLE; 130130), a protease that degrades elastin of the 
alveolar walls as well as other structural proteins of a 
variety of tissues (review by Cox, 2001) [23]. Long et 
al., 1984 [24] found that the genomic length of the PI 
gene is 10.2 kb with a 1,434-bp coding region. The 
gene has 4 introns; exon 1, the 5-prime portion of 
exon 2, and the 3-prime portion of exon 5 are 
noncoding regions. The first intron, 5.3 kb long, 
contains a 143-amino acid open reading frame (which 
does not appear to be an actual protein coding 
region), an Alu family sequence, and a 
pseudotranscription initiation region.  
 At the moment there are 40 allelic variants of 
SERPINA1 gene (Table 2). We investigated three 
allelic variants (PiM, PiZ and PiS alleles). PI Z allele 
(.0011, PI, GLU342LYS ON M1A 
[dbSNP:rs28929474]) is the most frequent allele 
leading to a high risk of emphysema (and liver 
disease) in the homozygote; the allele frequency is 
0.01-0.02 in US Caucasians (Crystal, 1989) [25]. 
Nukiwa et al., 1986 [26] demonstrated the val213-to-
ala substitution (here symbolized M1A) in PI*Z in 
addition to the disease-producing glu342-to-lys 
mutation. Ala213 was found in all of 40 Z haplotypes, 
using synthetic oligonucleotide gene probes directed 
toward the mutated exon 3 sequences in the Z gene. 
PI M(MALTON) (.0012 PI, PHE52DEL ON M2) as 
liver disease, as well as emphysema, has been 
described in patients with the rare PI*M(Malton) allele.  
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Table 2: Current Allelic Variants of Serpin Peptidase Inhibitor, 
Clade A, Member 1; SERPINA1 (OMIM 107400). 
Number ▲  Phenotype  Mutation  dbSNP 
.0001  PI M1-ALA213  
PI, M1A  
PI, ALA213  [rs6647]  
.0002  PI M1-VAL213  
PI, M1V  
PI, ALA213  [rs6647]  
.0003  PI M2  PI, ARG101HIS ON M3  [rs709932]  
.0004  PI M3  PI, GLU376ASP ON 
M1V  
[rs1303]  
.0005  PI M4  PI, ARG101HIS ON 
M1V  
-  
.0006  PI B(ALHAMBRA)  PI, ASP-LYS  -  
.0007  PI F  PI, ARG223CYS ON 
M1V  
[rs28929470]  
.0008  PI P(ST. ALBANS)  PI, ASP341ASN ON 
M1V  
[rs28929471], 
[rs143370956]  
.0009  PI X  PI, GLU204LYS ON 
M1V  
[rs199422208]  
.0010  PI CHRISTCHURCH  PI, GLU363LYS  [rs121912712]  
.0011  PI Z  PI, GLU342LYS ON 
M1A  
[rs28929474]  
.0012  PI M(MALTON)  PI, PHE52DEL ON M2  -  
.0013  PI S  PI, GLU264VAL ON 
M1V  
[rs17580]  
.0014  PI M(HEERLEN)  PI, PRO369LEU ON 
M1A  
[rs199422209]  
.0015  PI M(MINERAL SPRINGS)  PI, GLY67GLU ON M1A  [rs28931568]  
.0016  PI M(PROCIDA)  PI, LEU41PRO ON M1V  [rs28931569]  
.0017  PI M(NICHINAN)  PI, PHE52DEL AND 
GLY148ARG  
-  
.0018  PI I  PI, ARG39CYS ON M1V  [rs28931570]  
.0019  PI P(LOWELL)  
PI NULL(CARDIFF) 
PI Q0(CARDIFF)  
PI, ASP256VAL ON 
M1V  
[rs121912714]  
.0020  PI NULL(GRANITE FALLS)  
PI Q0(GRANITE FALLS)  
PI, TYR160TER ON 
M1A  
-  
.0021  PI NULL(BELLINGHAM)  
PI Q0(BELLINGHAM)  
PI, LYS217TER ON 
M1V  
[rs199422211]  
.0022  PI NULL(MATTAWA)  PI, LEU353PHE ON 
M1V  
[rs28929473]  
.0023  PI NULL(PROCIDA)  
PI NULL(ISOLA DI 
PROCIDA) 
PI Q0(PROCIDA)  
PI, 17-KB DEL  -  
.0024  PI NULL(HONG KONG 1)  
PI Q0(HONG KONG 1)  
PI, 2-BP DEL, 
FS334TER  
-  
.0025  PI NULL(BOLTON)  
PI Q0(BOLTON)  
PI, 1-BP DEL  -  
.0026  PI PITTSBURGH  
'ANTITHROMBIN' 
PITTSBURGH  
PI, MET358ARG  [rs121912713]  
.0027  PI V(MUNICH)  PI, ASP2ALA ON M1V  [rs199422212]  
.0028  PI Z(AUGSBURG)  
PI Z(TUN)  
PI, GLU342LYS ON M2  -  
.0029  PI W(BETHESDA)  PI, ALA336THR ON 
M1A  
[rs1802959]  
.0030  PI NULL(DEVON)  
PI Q0(DEVON) 
PI NULL(NEWPORT) 
PI Q0(NEWPORT)  
PI, GLY115SER  [rs11558261]  
.0031  PI NULL(LUDWIGSHAFEN)  
PI Q0(LUDWIGSHAFEN)  
PI, ILE92ASN  [rs28931572]  
.0032  PI Z(WREXHAM)  PI, SER-19LEU  [rs140814100]  
.0034  PI NULL(HONG KONG 2)  
PI Q0(HONG KONG 2)  
PI  -  
.0035  PI NULL(RIEDENBURG)  PI, DEL  -  
.0036  PI KALSHEKER-POLLER  PI, G-A, 3-PRIME UTR 
ENHANCER  
-  
.0037  PI P(DUARTE)  PI, ASP256VAL  -  
.0038  PI NULL(WEST)  
PI Q0(WEST)  
PI, IVS2DS, G-T, +1  -  
.0039  PI S(IIYAMA)  PI, SER53PHE  [rs55819880]  
.0040  PI Z(BRISTOL)  PI, THR85MET ON M1V  [rs199422213]  
 
 
Fraizer et al., 1989 [27] studied the molecular 
defect in M(Malton), a deficiency allele which, like the 
Z allele, is associated with hepatocyte inclusions and 
impairs secretion. They found that the M(Malton) 
allele contains a deletion of the codon for 1 of the 2 
adjacent phenylalanine residues (amino acid 51 or 52 
of the mature protein). Judging from the haplotype 
data, the M(Malton) mutation must have derived from 
the normal M2 allele. Deletion of the 1 amino acid 
would be expected to shorten 1 strand of the beta-
sheet, B6, apparently preventing normal processing 
and secretion. Curiel et al., 1989 [28] also showed 
that the M(Malton) allele differs from the normal M2 
allele by deletion of the entire codon (TTC) for residue 
phe52. They demonstrated abnormal intracellular 
accumulation of newly synthesized AAT protein in a 
homozygote that also showed, on liver biopsy, 
inflammation, mild fibrosis, and intrahepatocyte 
accumulation of the protein. PI S (.0013 PI, 
GLU264VAL ON M1V [dbSNP:rs17580]) was 
described by Owen and Carrell 1976 [29] and Yoshida 
et al., 1977 [30] who found substitution of valine for 
glutamic acid at position 264 in the S variant of alpha-
1-antitrypsin (Long et al. 1984 [31]). Curiel et al., 1989 
[32] concluded that the S-type AAT protein is 
degraded intracellularly before secretion. PI*S 
homozygotes are at no risk of emphysema, but 
compound heterozygotes with Z or a null allele have a 
mildly increased risk. Because of the high frequency 
of the PI*S allele (0.02-0.04 in US Caucasians), such 
compound heterozygotes are relatively frequent. 
 We described first allelic variants of 
SERPINA1 gene in Macedonians with reverse 
hybridization method and concentration of AAT in 
serum of eleven patients with different combinations 
of alleles. The number of investigated patients is very 
small and we need more genotyping of SERPINA1 
gene in order to analyze frequency and/or association 
studies. 
In conclusion, a diagnosis in the case of a 
suspicion of AAT deficiency is carried out by 
measuring the alpha-1-antitrypsin level in blood and 
by genotyping of alpha-1-antytripsin allele. The 
importance of early diagnosis or diagnosis early in life, 
resides in the possibility of smoking cessation and 
treatment of pulmonary disease which could 
significantly decrease the morbidity associated with 
this chronic disease.   
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